Background-Prostaglandin E 2 (PGE 2 ) is important in ductus arteriosus (DA) patency, but the types of functional PGE 2 receptors (EP) in the developing DA are not known. We postulated that age-dependent alterations in EP and/or their subtypes may possibly contribute to the reduced responsiveness of the newborn DA to PGE 2 . Methods and Results-We determined PGE 2 receptor subtypes by competition binding and immunoblot studies on the DA of fetal (Ϸ75% and 90% gestation) and newborn (Ͻ45 minutes old) pigs. We studied the effects of EP receptor stimulation on cAMP signaling in vitro and on term newborn (Ͻ3 hours old) DA patency in vivo. Fetal pig DA expressed EP 2 , EP 3 , and EP 4 receptors equivalently, but not EP 1 . In neonatal DA, EP 1 , EP 3 , and EP 4 were undetectable, whereas EP 2 density was similar in fetus and newborn. Prostaglandin-induced changes in cAMP mirrored binding data. 16,16-Dimethyl PGE 2 and 11-deoxy PGE 1 (EP 2 /EP 3 /EP 4 agonist) produced more cAMP in fetus than newborn, but butaprost (selective EP 2 agonist) caused similar cAMP increases in both; EP 3 and EP 4 ligands (M&B28767 and AH23848B, respectively) affected cAMP production only in fetus. After birth, administration of butaprost alone was as effective as 11-deoxy PGE 1 and 16,16-dimethyl PGE 2 in dilating DA in vivo. Conclusions-The data reveal fewer PGE 2 receptors in the DA of the newborn than in that of the fetus; this may contribute to the decreased responsiveness of the DA to PGE 2 in newborn. Because EP 2 receptors seem to mediate the effects of PGE 2 on the newborn DA, one may propose that a selective EP 2 agonist may be preferred as a pharmacological agent to maintain DA patency in infants with certain congenital heart diseases. (Circulation. 1999;100:1751-1756.)
P
rostaglandins play a major role in maintaining patency of the fetal ductus arteriosus (DA). 1, 2 The marked sensitivity of the DA to prostaglandin E 2 (PGE 2 ) suggests that this is the most important prostanoid regulating vessel patency. 3 PGE 2 exerts its effects through a diverse group of receptors, classified as EP 1 , EP 2 , EP 3 , and EP 4 . 4 Activation of EP 1 increases inositol 1,4,5-triphosphate (IP 3 ) formation and elicits vasoconstriction, 5 stimulation of EP 2 and EP 4 increases cAMP and leads to vasodilation, 4, 6 and stimulation of EP 3 decreases cAMP and opposes vasodilation. 4 At present, the relative types and importance of EP receptors in the DA are uncertain. Pharmacological evidence suggests that the EP 4 receptor is the predominant PGE 2 receptor in the fetal rabbit DA. 7 Conversely, genetic disruption of the EP 4 receptor does not diminish DA patency in the fetal and neonatal mouse. 8 However, the type of EP receptors expressed in higher species, and especially in the newborn, is not known. This is of particular relevance because responsiveness of the DA to PGE 2 in the newborn is significantly less than that in the fetus. 9, 10 Because PGE 2 acts on several distinct receptor subtypes, each coupled to different second messengers, we hypothesized that differences in the relative density and/or proportion of EP receptors could explain, at least in part, the differences in the responsiveness of the fetal and neonatal DA to PGE 2 . 9, 10 We therefore studied the expression of EP receptor subtypes and EP receptor signaling factors in the DA of fetal and newborn pigs. We also assessed the role of these receptors in the newborn in vivo. Our findings reveal that the DA of the fetal pig expresses negligible amounts of the EP 1 receptor but does express the other 3 EP subtypes (EP 2 , EP 3 , EP 4 ) in equivalent proportions. In the DA of the newborn pig, the density of PGE 2 receptors is significantly reduced compared with that in the fetus because of complete loss of EP 3 and EP 4 receptors; however, the number of EP 2 receptors remains unchanged, such that EP 2 seems to mediate all PGE 2 -dependent relaxation in the newborn DA.
Methods

Animals
DAs were removed from fetal pigs (78 to 90 and 100 to 105 days of gestation [term, 114 days]) and term newborn piglets (1.25 to 1.7 kg, killed within 45 minutes of vaginal birth with pentobarbital [120 mg/kg intracardiac] under halothane anesthesia). Tissues were immediately rinsed in ice-cold Krebs buffer (pH 7.4) of the following composition (mmol/L): NaCl 120, KCl 4.5, CaCl 2 2.5, MgSO 4 1.0, NaHCO 3 27, KH 2 PO 4 1.0, and glucose 10 and then frozen in liquid N 2 ; we have shown that freezing does not affect PGE 2 binding. 11 A group of newborn piglets (Ͻ3 hours old) was used to study the effects of prostaglandin analogues on DA diameter in vivo.
EP Receptor Characterization
Tissues were prepared for prostaglandin binding as described. 11 
Immunoblotting of EP Receptors
Western blotting of EP 1 , EP 3␣ , and EP 4 receptors was conducted 15 on DA membranes prepared as described 13 and on cell lysates from human embryonic kidney (HEK) 293 cells (Invitrogen), which overexpress each of these receptors 16 and hence were used as positive controls. After immunoblotting with EP 1 , EP 3␣ , or EP 4 specific polyclonal rabbit antibodies 17 (1:1000; EP 2 antibodies are not available), immunoreactive bands were visualized by chemiluminescence (Amersham) according to the manufacturer's instructions.
cAMP Assay
The effects of PGE 2 analogues on cAMP were determined. 12, 13 Briefly, DA homogenates (100 g protein) were incubated in an assay mixture (100 L) containing 10 mmol/L Tris-HCl buffer (pH 8.0), 1 mmol/L ATP, 7.5 mmol/L MgCl 2 , 15 mmol/L creatine phosphate, 185 U/mL creatine phosphokinase, 200 g/mL aspirin, 0.5 mmol/L EGTA, 0.5 mmol/L 3-isobutyl-1-methylxanthine, 1 mmol/L dithiothreitol, 1 mmol/L benzamidine, 0.1 mmol/L phenylmethylsulfonyl fluoride, and 100 g/mL soybean trypsin inhibitor in the presence or absence of test agents at 37°C for 10 minutes. The reaction was terminated with 200 L acidic ethanol. After centrifugation, cAMP was measured by radioimmunoassay (Diagnostic Products).
Surgical Preparation and Echocardiography
Newborn pigs (between 1.5 and 2 hours after delivery; 1.3 to 1.7 kg) were prepared to test the effects of specific EP receptor agonists on DA patency; in the piglet, the DA closes completely by 4 to 6 hours of age. 18 We were not able to perform in vivo studies on fetal pigs because facilities were not available to operate on sows. The newborn piglets were anesthetized with halothane (2%) for 15 minutes during tracheostomy and catheterization of the umbilical vein and artery, and anesthesia was discontinued after surgery. Animals were ventilated with air with a Harvard small-animal respirator, maintained on ␣-chloralose (50 mg/kg bolus followed by 10 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 infusion), and paralyzed with pancuronium (0.1 mg/kg); body temperature was maintained at 38°C. The surgical procedure was completed within 15 minutes, and piglets were allowed to stabilize for an additional 30 minutes.
Echocardiographic measurements were performed with an Acuson 128 XP/10C real-time ultrasound imaging system using 7.5-and 5-MHz transducers duplexed with a range-gated Doppler as previously described 19, 20 ; Doppler signals were filtered by 100-Hz highpass filter. The DA was visualized through a left second intercostal parasternal approach. Measurements of the DA diameter were repeated 3 times. The smallest diameter of the DA lumen was monitored until it reached 0.6 to 0.8 mm in diameter. Experimental drugs were then injected, and the smallest diameter was measured every minute for the next 10 to 25 minutes.
Animals (3 to 4 per treatment) were randomly assigned to receive 10-minute infusions of saline (1 mL, controls) or 0.083 g ⅐ kg Ϫ1 ⅐ min Ϫ1 of EP receptor agonists; the doses used have been shown previously to be effective in vivo. 21 The effect of EP receptor agonists on DA patency was also tested in animals pretreated with indomethacin (3 mg/kg IV for 5 minutes), once the DA diameter reached 0.6 to 0.9 mm (within 20 minutes).
Statistical Analysis
Data were analyzed by Student's t test and by 2-way ANOVA factoring for time and treatment; means tests were compared by the Tukey-Kramer method. Statistical significance was set at PϽ0.05. Data are expressed as meanϮSEM. Figure 1D and Table 2 ). IC 50 values of ligands tested were comparable to those reported in other porcine tissues. 11, 12 Results indicate the presence of EP 2 , EP 3 , and EP 4 in fetal DA.
Results
PGE 2 Receptors in Fetal and
In the immediate postnatal newborn, EP 3 and EP 4 are absent, without significant change in the number of EP 2 receptors ( Figure 1E) and 11-deoxy PGE 1 (EP 2 /EP 3 /EP 4 agonist) produced a comparable dose-dependent increase in cAMP synthesis, which was greater in fetus than in newborn (Table 3) . In fetal DA, butaprost (EP 2 agonist) stimulated cAMP production in a concentration-dependent manner. The EP 3 agonist M&B28,767 and EP 1 /EP 3 agonist sulprostone had no effect on cAMP formation by themselves but reduced forskolin-induced cAMP synthesis; this suggests that EP 3 is coupled to inhibition of cAMP formation. Because no selective EP 4 agonist is currently available, we estimated the effects attributed to EP 4 , as we previously reported, 12 by subtracting the increase in cAMP produced by the combination of 16,16-dimethyl PGE 2 and EP 4 antagonist AH23848B (which would stimulate all of the EP receptors except EP 4 ) from the increase in cAMP produced by 16,16-dimethyl PGE 2 alone (which stimulates all EP receptors). In the fetal DA, AH23848B decreased the cAMP production induced by 16,16-dimethyl PGE 2 but not that stimulated by butaprost (Table 3 ). In the newborn DA, butaprost increased cAMP generation to values comparable to those in the fetus (Table 3) ; M&B28,767, sulprostone, and AH23848B had no effect on cAMP production.
Effects of EP Receptor Agonists on DA Diameter In Vivo
We examined the effects of EP receptor agonists (17-phenyltrinor PGE 2 (Figure 3) . 16,16-Dimethyl PGE 2 dilated both the untreated, spontaneously closing ( Figure 3A ) and the indomethacin-constricted DA ( Figure 3B ). Butaprost and 11-deoxy PGE 1 dilated the constricting DA as seen with 16,16-dimethyl PGE 2 ( Figure 3) ; cessation of infusion of these PGE 2 analogues resulted in constriction of the DA. In contrast, 17-phenyl-trinor PGE 2 , M&B28,767, and sulprostone did not affect DA diameter; 2-to 3-fold higher infusion rates of the EP 1 and EP 3 agonists also had no effects (data not shown). Hence, the vasodilatory effects of PGE 2 in the newly born seem to be accounted for by action on EP 2 .
Discussion
Previous pharmacological studies have suggested that EP 4 is the dominant (relaxant) PGE 2 receptor in the fetal rabbit DA. 7 In the mouse, however, disruption of the EP 4 gene did not affect ductal patency, 8 suggesting possible species differences. We therefore set out to characterize the EP receptors in the DA of the fetus and newborn of a higher species, namely the pig.
Using binding and displacement, immunoblot, and stimulation of second-messenger cAMP, our studies revealed that the number and types of PGE 2 receptors differ between fetal and immediate postnatal newborn DA. There was a 3-fold higher density of PGE 2 receptors and a greater PGE 2 -induced increase in cAMP in the fetus than in the newborn (Table 3) ; a rise in cAMP is usually associated with vasorelaxation. 6 We identified EP 2 , EP 3 , and EP 4 receptors in the fetal pig DA; EP 1 receptor was undetectable (Figures 1 and 2 ). In the newborn DA, we observed a decrease in PGE 2 binding due to a loss of EP 3 and EP 4 receptors ( Figures 1C through 1E and 2) ; the number of EP 2 receptors was essentially the same in the fetus and newborn. As a result, the EP 2 receptor appeared to mediate the vasorelaxant effects of PGE 2 on the full-term neonatal DA (Figure 3) . The mechanism(s) responsible for the birth-related decrease in PGE 2 receptors in the DA are currently unknown. We have previously observed that the loss of DA responsiveness to PGE 2 is directly related to the degree of postnatal DA constriction. 9 However, a role for hypoxia to explain the selective loss of EP 3 and EP 4 is unlikely. Our data on [ 3 H]PGE 2 binding, immunoreactivity, and cAMP generation in newborn were obtained on DA of animals Ͻ45 minutes after birth. Although a 50% ductal constriction occurs over this time period, 18 the partial pressure of oxygen also rises markedly immediately after birth; as a result, the DA tunica media may not develop significant hypoxia during this time period. In support of this inference, tissues from 15-minuteold newborn animals exhibited [ 3 H]PGE 2 binding properties similar to those of piglets 30 to 45 minutes old (data not shown). Another more likely explanation for the changes in EP receptor profile after birth relates to the sharp increase in PGE 2 concentrations in both the DA and the circulating plasma during the perinatal period. 3, 20, 22, 23 We have previously observed that EP 3 and EP 4 receptors in cerebral and ocular vessels can be altered by high levels of circulating PGE 2 concentrations in the perinatal period. 12,13 EP 2 receptors, conversely, do not appear to be regulated by PGE 2 concentrations. 12 We speculate that the EP receptors in the DA also may undergo this same type of homologous downregulation during the perinatal period when plasma PGE 2 levels peak at the end of labor. 24 Although PGE 2 levels decrease immediately after birth to reach fetal values by 1 to 2 hours, 24 this time period is insufficient to reverse the downregulation of PGE 2 receptors. 13 A reduction in PGE 2 receptors associated with a decrease in PGE 2 -induced cAMP formation in the immediately postnatal newborn is consistent with and may contribute to the reduced responsiveness to PGE 2 of the newborn DA compared with that of the fetus. 9, 10 In the present study, we focused on ontogenic changes in PGE 2 receptors in the DA. Other mechanisms are also likely to participate in this age-dependent altered responsiveness of the DA to PGE 2 . 9, 10 These include developmental changes in the rates of prostaglandin production, uptake, and degradation as well as in prostaglandin-coupled signal transduction and relaxant mechanisms, and the role of increasing oxygen tension on ductal Effects of PGE 2 receptor agonists on DA diameter in newborn pigs. A, DA diameter in newborn pigs after infusion of saline (E), 16,16-dimethyl PGE 2 ( f ), EP 2 /EP 3 /EP 4 agonist 11-deoxy PGE 1 ( OE ), EP 1 agonist 17-phenyl-trinor PGE 2 ( Ⅺ ), EP 2 agonist butaprost (F), EP 3 agonist M&B28,767 ( ƒ ), or EP 1 /EP 3 agonist sulprostone (‚); diameter of aorta at isthmus was 5.8Ϯ0.9 mm. Effects of agents were studied when DA closed spontaneously to reach a diameter of 0.6 to 0.8 mm (at Ϸ2.5 to 3 hours old). Shaded area along abscissa corresponds to period of PGE 2 analogue infusion (0.083 g ⅐ kg Ϫ1 ⅐ min Ϫ1 IV). B, DA diameter of newborn pigs (1.5 hours old) first treated with indomethacin (INDO, 3 mg/kg IV) and subsequently infused with saline (E), 16,16-dimethyl PGE 2 (f), 17-phenyl-trinor PGE 2 ( Ⅺ ), butaprost (F), or M&B28,767 ( ƒ ). Shaded area along abscissa corresponds to period of PGE 2 analogue infusion (0.083 g ⅐ kg Ϫ1 ⅐ min Ϫ1 IV). Arrow points to time of administration of indomethacin. Effects of PGE 2 analogues were determined on DA when it reached a diameter similar to that in A. Ductal diameter was measured by echocardiogram as described in Methods section. Values are meanϮSEM of 3 to 4 experiments for each agent. *PϽ0.05 vs corresponding values for saline, 17-phenyltrinor PGE 2 , M&B28,767, and sulprostone (ANOVA and TukeyKramer method).
function, 25 which has been debated 26 ; these various aspects need to be examined separately.
In summary, the present study demonstrates a developmental alteration of EP receptors in the DA. However, changes in EP receptor profile in DA of the prematurely born newborn remain to be determined. The present study also provides a physiological basis for the potential use of more selective EP receptor ligands to control DA patency and potentially diminish the side effects associated with nonselective PGE therapy. 27 For example, one could suggest specific therapies for maintaining ductal patency in infants with congenital heart disease, such as selective EP 2 agonists, and possibly reduce PGE 2 -mediated fever due to EP 3 stimulation. 28 In the future, selective EP receptor antagonists targeted toward inflammation, 29 fever, 28 and pain 21 in the pregnant subject will also need to be evaluated for their effects on the fetal DA.
